2025-01-31 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO):**

Intuitive Surgical Inc. (ISRG) is a company that develops and markets the da Vinci surgical system, a robotic surgery system.  Over the period analyzed, ISRG significantly outperformed the S&P 500 (VOO).  The cumulative return for ISRG is 323.13%, while the S&P 500's cumulative return is 121.09%.  The difference in cumulative returns is a substantial 202.04%. This places ISRG at the 90.7th percentile of its historical performance relative to the S&P 500, based on the provided data.  While high, this relative performance is subject to the historical period used in the calculation.


**2. Recent Price Movement:**

As of the last reported data point, ISRG closed at $580.18.  The stock shows a recent upward trend:

* **5-day moving average:** $576.91
* **20-day moving average:** $564.51
* **60-day moving average:** $545.08

The price is above all three moving averages, suggesting a positive short-term momentum.  The recent increase from the previous close ($572.71) of $1.30 further supports this.


**3. Technical Indicators and Expected Return:**

* **RSI (63.89):** Suggests the stock is neither overbought nor oversold, indicating a neutral to slightly bullish sentiment.
* **PPO (-0.10):** A negative PPO suggests a potential bearish trend, although its proximity to zero suggests that the trend might be weakening or about to reverse.
* **Relative Divergence:** A recent negative change of -8.2% in relative strength suggests a short-term downward correction or consolidation. This is countered by the positive price movement noted in the previous section.
* **Expected Return (21.2%):**  A projected 21.2% excess return over the S&P 500 over the long term (2+ years) suggests significant potential for outperformance.  This needs to be considered in the context of inherent risk.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-10-18 | $1.59  | $2.04B      |
| 2024-07-19 | $1.48  | $2.01B      |
| 2024-04-19 | $1.54  | $1.89B      |
| 2023-10-20 | $1.18  | $1.74B      |
| 2023-10-18 | $1.18  | $1.74B      | *(Note: Duplicate entry likely a data error)*

Earnings show a relatively stable to increasing trend in both EPS and revenue, indicating strong company performance.  The apparent duplication in October 2023 needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2024-09-30 | $2.04B  | 67.41%        |
| 2024-06-30 | $2.01B  | 68.30%        |
| 2024-03-31 | $1.89B  | 65.87%        |
| 2023-12-31 | $1.93B  | 66.24%        |
| 2023-09-30 | $1.74B  | 66.94%        |

Revenue shows consistent growth, and Profit Margin remains relatively high and stable, suggesting strong financial health.

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2024-09-30 | $15.58B  | 3.63%   |
| 2024-06-30 | $14.71B  | 3.58%   |
| 2024-03-31 | $13.96B  | 3.90%   |
| 2023-12-31 | $13.31B  | 4.56%   |
| 2023-09-30 | $12.54B  | 3.32%   |

Equity is increasing steadily, although ROE fluctuates.  The overall trend shows financial strength.

**7. Overall Summary:**

ISRG demonstrates strong historical performance significantly outpacing the S&P 500.  Recent price action, while showing a minor correction according to the relative strength index, is overall positive and above its moving averages.  Earnings and financial statements indicate strong and stable company health. While the PPO suggests potential bearishness, the overall picture, particularly the high long-term expected return, paints a positive outlook for long-term investors. However, investors should be mindful of the inherent risk involved in any investment and conduct further due diligence before making any investment decisions.  The duplicated earnings data point requires further investigation to ensure data accuracy.
